A Potential Breakthrough in HIV Research
Researchers may have moved closer to finding a cure for HIV by discovering a method to draw the virus out from its hidden state within human cells.
The primary hurdle has been the virus’s ability to stay concealed in certain white blood cells, creating a reservoir that neither the immune system nor medications can effectively combat.
A team from the Peter Doherty Institute for Infection and Immunity in Melbourne has revealed a technique to visualize the virus, which could lead to its complete eradication from the body.
This approach utilizes mRNA technology, which gained attention during the Covid-19 pandemic through vaccines developed by companies like Moderna and Pfizer/BioNTech.
In a study published in Nature Communications, researchers demonstrated how mRNA can be delivered to the cells harboring HIV by surrounding it with tiny, specially formulated lipid nanoparticles. This mRNA instructs the cells to uncover the virus.
Currently, nearly 40 million individuals worldwide live with HIV and must continue lifelong medication to manage the virus and prevent symptoms or transmission. Tragically, according to UNAids, one person dies from HIV every minute.
Dr. Paula Cevaal, a research fellow at the Doherty Institute and co-first author of the study, noted that delivering mRNA to the type of white blood cells housing HIV was previously considered unattainable since those cells didn’t absorb the lipid nanoparticles effectively.
The team developed a new lipid nanoparticle variant, named LNP X, which those cells can accept. Cevaal expressed hope that this innovative design could pave the way for an HIV cure.
When the test results were first shared at a weekly lab meeting, Cevaal confessed they seemed almost too promising. Her colleague repeated the tests, and upon returning with equally impressive results, the team was left in awe. “It was as if we had witnessed a night-and-day difference,” she recalled.
Now, further research is vital to ascertain if simply revealing the virus will empower the immune system to eliminate it, or whether this breakthrough needs to be integrated with other treatments.
The ongoing study primarily involved laboratory work with cells donated by HIV patients. Transforming this technology into an actual treatment requires extensive testing in animals and later safety trials in humans, a process that could span years before reaching efficacy trials.
In the world of biomedicine, many potential solutions never make it to clinical use, Cevaal acknowledged, emphasizing a realistic perspective. However, she noted that they hadn’t seen anything as promising in the HIV research field in terms of visibility into this virus.
Dr. Michael Roche from the University of Melbourne, co-senior author of the research, suggested that this discovery might offer broader benefits, as the targeted white blood cells also play roles in other diseases, including various cancers.
Dr. Jonathan Stoye, a retrovirologist and emeritus scientist at the Francis Crick Institute who was not involved with the research, regarded the Melbourne team’s method as a significant advancement over current efforts to bring the virus to light. But he mentioned that more studies are necessary to figure out the most effective means to eliminate it thereafter.
He raised a crucial question: Is it necessary to eliminate the entire reservoir of the virus for success, or just a significant portion? “If only 10% of the latent reservoir remains, could that lead to new infections?” he pondered.
Despite these unknowns, he emphasized that the study’s significance lies in its potential for mRNA delivery to blood cells.
Contrarily, Prof. Tomáš Hanke from the Jenner Institute at the University of Oxford contended that delivering RNA into white blood cells hasn’t been a notable challenge. He expressed skepticism about the notion that all cells harboring HIV could be targeted effectively through this method.
